Valneva SE

Valneva, incorporated in 2013 and headquartered in Saint-Herblain, France, is a specialist vaccine company. The business primarily focuses on the development and commercialization of vaccines for infectious diseases. The company plays a significant role in the travel vaccines market, providing immunization products for diseases commonly encountered by international travelers. In its portfolio, Valneva offers notable brands like IXIARO®/JESPECT®, which are vaccines aimed at preventing Japanese encephalitis, and DUKORAL®, an oral vaccine designed to protect against cholera and traveler's diarrhea caused by ETEC (Enterotoxigenic Escherichia coli). The company is also engaged in the development of new vaccine candidates, which includes research into vaccinations for Lyme disease and chikungunya, reflecting its commitment to addressing global health concerns. Valneva's products and services have a vast reach, with a significant presence in various key markets worldwide. Its vaccines are predominantly sold in Europe, where there is a high demand for its travel vaccines. The North American market is an important region for its travel-related and endemic disease vaccines, while the Asia-Pacific region is a notable market for its Japanese encephalitis vaccines. Additionally, Valneva caters to a range of other international markets, particularly areas with prevalent risks of the diseases targeted by its vaccine offerings. (Powered by AI)